Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Merck
Colorcon
Mallinckrodt
McKinsey
Cantor Fitzgerald

Generated: June 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,680,111

« Back to Dashboard

Which drugs does patent 8,680,111 protect, and when does it expire?

Patent 8,680,111 protects LORBRENA and is included in one NDA.

This patent has fifty patent family members in forty-two countries.

Summary for Patent: 8,680,111
Title:Macrocyclic derivatives for the treatment of diseases
Abstract: The invention relates to compounds of formula (.PHI.) ##STR00001## as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Inventor(s): Bailey; Simon (San Diego, CA), Burke; Benjamin Joseph (San Diego, CA), Collins; Michael Raymond (San Diego, CA), Cui; Jingrong Jean (San Diego, CA), Deal; Judith Gail (Wildomar, CA), Hoffman; Robert Louis (San Marcos, CA), Huang; Qinhua (San Diego, CA), Johnson; Ted William (Carlsbad, CA), Kania; Robert Steven (San Diego, CA), Kath; John Charles (La Mesa, CA), Le; Phuong Thi Quy (San Diego, CA), McTigue; Michele Ann (Encinitas, CA), Palmer; Cynthia Louise (La Mesa, CA), Richardson; Paul Francis (San Diego, CA), Sach; Neal William (San Diego, CA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:13/786,106
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,680,111
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,680,111

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer Inc LORBRENA lorlatinib TABLET;ORAL 210868-001 Nov 2, 2018 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Pfizer Inc LORBRENA lorlatinib TABLET;ORAL 210868-002 Nov 2, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Julphar
QuintilesIMS
Farmers Insurance
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.